#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14452	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2333	758.9	0	.	n	.	0	A69G	SNP	69	69	A	436	436	G	901	G,A	646,254	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14452	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2333	758.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1817	1817	T	948	T,G,A	944,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14452	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2333	758.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1551	1551	C	935	C,A	934,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24272	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3837	786.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1798	1798	A	1015	A	1015	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24272	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3837	786.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2432	2432	C	830	C,G	829,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24272	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3837	786.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2506	2506	A	774	A,G,C	772,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24272	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3837	786.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3058	3058	C	842	C,T	841,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2170	folP	852	852	99.88	folP.l15.c4.ctg.1	2043	132.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1064	1066	AAA	233;229;227	A;A;A	233;229;227	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2170	folP	852	852	99.88	folP.l15.c4.ctg.1	2043	132.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1295	1297	AGC	201;202;201	A;G;C	201;202;201	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5158	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3906	164.6	1	SNP	p	S91F	0	.	.	271	273	TCC	860	862	TCC	190;189;192	T,A;C;C	189,1;189;192	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5158	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3906	164.6	1	SNP	p	D95G	0	.	.	283	285	GAC	872	874	GAC	201;201;201	G;A,C;C	201;200,1;201	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5158	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3906	164.6	1	SNP	p	D95N	0	.	.	283	285	GAC	872	874	GAC	201;201;201	G;A,C;C	201;200,1;201	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1886	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1634	143.4	1	SNP	p	G45D	0	.	.	133	135	GGC	660	662	GGC	202;202;203	G;G;C	202;202;203	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1010	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1458	86.2	0	.	n	.	0	A197.	DEL	197	197	A	870	870	A	206	A	206	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4976	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3376	183.5	1	SNP	p	D86N	0	.	.	256	258	GAC	801	803	GAC	228;229;229	G,T;A;C,A	227,1;229;228,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4976	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3376	183.5	1	SNP	p	S87I	0	.	.	259	261	AGT	804	806	AGT	228;226;227	A,C;G;T,A	227,1;226;226,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4976	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3376	183.5	1	SNP	p	S87R	0	.	.	259	261	AGT	804	806	AGT	228;226;227	A,C;G;T,A	227,1;226;226,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4976	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3376	183.5	1	SNP	p	S87W	0	.	.	259	261	AGT	804	806	AGT	228;226;227	A,C;G;T,A	227,1;226;226,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4976	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3376	183.5	1	SNP	p	S88P	0	.	.	262	264	TCC	807	809	TCC	229;226;228	T;C,A;C,A	229;225,1;227,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4062	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3082	164.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1736	1738	GGC	248;245;247	G,T;G,C,A;C,T,G	247,1;243,1,1;245,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1467	1469	GCA	227;229;231	G;C;A	227;229;231	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1470	1472	ATC	230;228;228	A;T,G,A;C,A	230;226,1,1;227,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1482	1484	GTG	237;239;244	G,C;T;G	236,1;239;244	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1482	1484	GTG	237;239;244	G,C;T;G	236,1;239;244	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1986	1988	ACC	200;202;201	A;C;C	200;202;201	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2040	2042	GCG	221;219;220	G,T;C;G	220,1;219;220	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2040	2042	GCG	221;219;220	G,T;C;G	220,1;219;220	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2163	2165	GGC	199;196;199	G;G;C	199;196;199	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2172	2174	GGC	200;201;201	G,T;G,T;C,A	199,1;200,1;200,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	164.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2190	2192	CTG	218;221;220	C;T;G	218;221;220	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5380	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3611	185.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1856	1858	CCG	221;224;226	C,G;C;G	220,1;224;226	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2272	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2388	118.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	864	864	C	166	C,A	165,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	21;21;22	T;T;A	21;21;22	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	47;47;47	C;A;T	47;47;47	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	47;47;47	A;G;T	47;47;47	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	47;47;47	T;A;C	47;47;47	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	226	90.27	porB1a.l6.c17.ctg.2	289	21.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	100	95.0	porB1a.l6.c17.ctg.3	177	41.7	0	.	p	.	0	M18T	NONSYN	52	54	ATG	128	130	ACG	40;39;35	A;C;G	40;39;35	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	222	porB1a	984	100	95.0	porB1a.l6.c17.ctg.3	177	41.7	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	170	172	CAA	9;8;8	C;A;A	9;8;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	558	560	GAA	245;245;244	G;A,C;A	245;244,1;244	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	846	848	GAT	227;223;222	G,A;A;T,A	226,1;223;221,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	969	971	TCA	257;257;253	T,G;C;A	255,1;257;253	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	D212Y	NONSYN	634	636	GAT	1080	1082	TAT	204;202;199	T;A;T,G	204;202;197,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1098	1100	GTC	190;188;186	G;T,C;C	190;187,1;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1110	1112	TCT	201;202;202	T,G;C;T	199,2;202;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1428	1430	GCA	226;223;216	G;C,T;A,C	226;221,2;215,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	1	SNP	p	G120K	1	.	.	358	360	AAG	804	806	AAG	229;230;233	A;A;G	229;230;233	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	1	SNP	p	A121D	1	.	.	361	363	GAC	807	809	GAC	230;229;231	G,T;A;C	229,1;229;231	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2650	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1967	167.0	1	SNP	p	D121N	0	.	.	361	363	GAC	807	809	GAC	230;229;231	G,T;A;C	229,1;229;231	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9798	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5346	228.4	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2156	2158	AAT	242;241;240	A;A;T	242;241;240	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1334	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1384	119.8	1	SNP	p	V57M	1	.	.	169	171	ATG	699	701	ATG	213;214;215	A;T;G	213;214;215	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
